A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Sponsor:

AbbVie, Inc

Sponsor Study ID:

M25-274

CTO #:

104185

NCT Number:

NCT06568939

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

To evaluate the safety of telisotuzumab vedotin at the 1.9 mg/kg, 1.6 mg/kg, and 1.6 mg/kg ->; 1.9 mg/kg dose levels, as measured by the occurrence of any-grade AEs, Grade ≥ 2 AEs, ILD (any-grade and Grade ≥ 2), peripheral neuropathy (any-grade and Grade ≥ 2), ocular surface disorders (any-grade and Grade ≥ 2), AEs leading to discontinuation, and Grade 5 AEs. To evaluate the efficacy of telisotuzumab vedotin at the 1.9 mg/kg, 1.6 mg/kg, and 1.6 mg/kg → 1.9 mg/kg dose levels, as measured by objective response (OR)

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)